Concepedia

Linda Pestano

LP

16

Publications

1K

Citations

14

H-Index

2003

Active since

Affiliations

Miragen Therapeutics (United States)(Current)

University of Colorado Denver

Huntsman Cancer Institute

Yale Cancer Center

The University of Texas MD Anderson Cancer Center

Linda Pestano is an author at Miragen Therapeutics (United States) specializing in medicine, cancer therapeutics, and oncology.

Top concepts

Publications per year

2003–2022

16

Publications

16

A synthetic microRNA‐92a inhibitor (MRG‐110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds

Corrie L. Gallant‐Behm, Joseph Piper, Brent Dickinson et al. · Wound Repair and Regeneration · 2018 · 156 citations

Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study

Wesley Abplanalp, Ariane Fischer, David John et al. · Nucleic Acid Therapeutics · 2020 · 147 citations

Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>

Eleni Anastasiadou, Anita G. Seto, Xuan Beatty et al. · Clinical Cancer Research · 2020 · 145 citations · Full text

A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination

Ramesh K. Ramanathan, James L. Abbruzzese, Tomislav Dragovich et al. · Cancer Chemotherapy and Pharmacology · 2010 · 115 citations

, , +8

A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis

Maurizio Chioccioli, Subhadeep Roy, Rachel Newell et al. · EBioMedicine · 2022 · 106 citations · Full text

, , +10

Rows per page

1–5 of 16